Uncategorized

Enspire DBS Therapy, Inc., (Enspire) a clinical stage company developing an implantable neuromodulation therapy for post-stroke recovery, announced today the publication of the results of The EDEN trial (Electrical Stimulation of the Dentate Nucleus for Upper Extremity Hemiparesis Due to Ischemic Stroke), an early feasibility study led by Cleveland Clinic researchers, in Nature Medicine.

Cyclo Therapeutics, Inc. today reported its financial results for the second quarter 2023.

Biotricity Inc. today announced its financial results for the first quarter of fiscal 2024 year ended June 30, 2023.

Research has shown that a novel antibody generated to target an ‘essential amino acid sequence’ of both interleukin-17A and F has greater activity and potentially fewer side effects than existing biological therapies for conditions such as as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD).

ImmunoBrain Checkpoint Inc.today announced the appointment of James M. Mackay , Ph.D., to the Board of Directors. Mackay brings decades of biopharma leadership experience to the Company’s Board.

OnCusp Therapeutics announced today the clearance of its Investigational New Drug (IND) Application for CUSP06 by the U.S. Food and Drug Administration (FDA).

RegeneRx Biopharmaceuticals, Inc. announced that it has today effected a 1-for-100 reverse split in the outstanding shares of Common Stock of the Company and has filed the requisite Form 15 to suspend and terminate the Company’s continued obligations to file reports with the SEC pursuant to Sections 13(d) and 15(d) of the Securities Exchange Act

Clario, a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, today announced an expansion to its collaboration with AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology.

Invitae (NYSE: NVTA), a leading medical genetics company, today announced findings from its PROCLAIM trial, published in European Urology Oncology, showing that almost half of prostate cancer patients with clinically actionable pathogenic/likely pathogenic germline variants (PGVs) could be missing out on genetics-informed care due to restrictive criteria for genetic testing.

Microbion Corporation today announced that the company presented a poster highlighting the results from a series of in vitro and in vivo studies characterizing pravibismane’s effect against Mycobacteroides abscessus at the recent 6th World Bronchiectasis & NTM Conference held in New York, NY.